Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Aviva Lev-Ari, PhD, RN

https://lnkd.in/eEyn69r

(o) 1-617-244-4024 (m) 1-617-775-0451

avivalev-ari@alum.berkeley.edu

 

Director & Founder

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

Editor-in-Chief

http://pharmaceuticalintelligence.com

https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN

SkypeID: HarpPlayer83  LinkedIn Profile  Twitter Profile

 

1. Professional Preparation

 

UNIVERSITY OF CALIFORNIA, BERKELEY

Ph.D, 1978 – 1983

Industrial Organization Economics, Industrial Systems-Economic Geography, College of Letters & Science

Grade 3.75/4.00

Activities and Societies: ASA, ORSA

 

Stanford University Graduate School of Business

Exchange Program with UC Berkeley 11 courses of MBA Program

Area: Organization Behavior

1980 – 1981

 

Northeastern University

PreMed, 2005 – 2005

Biological and Biomedical Sciences, Four semesters, course load: 15 courses 2005

 

Northeastern University

Nursing, RN, 2005 – 2007

Bouve College of Health Sciences, School of Nursing, Four semesters of Independent Research in Cardiovascular Pharmacotherapy with Prof. Paul Abourjaily

Activities and Societies: ANA, MARN

 

Hebrew University of Jerusalem

BA, MA

Urban Planning, Economic Geography

GPA 95/100

1970 – 1976

Activities and Societies: Israel Poets Association

 

HUGGIM – High School, Mount Carmel, Haifa, Israel

Baccalaureate in Economics and Political Sciences, 93/100

1964 – 1968

 

2. Appointments

• Scientific and Medical Affairs Chronological CV
• Technology Executive, Methodology and Decision Scientist, Functional CV
• Contributions to Design of Algorithm-based Decision Support Systems
• Technical Contributions in the Domain of Electronic Commerce Analytics: Aviva Lev-Ari, Ph.D.
• HealthCare Delivery – Long Term Post Acute Care Nursing Management CV

 

3. Nominations for Awards & Honors

 

• On 12/6/2019 became Nominee for 2020 Campanile Excellence in Achievement Award. This award recognizes an alumnus/a whose remarkable professional lifetime achievements reflect the excellence of a UC Berkeley education. Nominator:  Sheila M. Puffer(UC, Berkeley, PhD’84).

Past Recipients

https://awards.berkeley.edu/achievement-awards

The recipients will be formally presented with their awards at Berkeley Charter Gala on May 14, 2020.

 

• On 3/31/2018, Dr. Lev-Ari, PhD, RN was nominated for the 2018 Yidan Foundation Prize

https://yidanprize.org/

Per request for supporting material, the following was submitted to the nominator, Prof. Marcus W. Feldman of Stanford University, Department of Biology.

Nomination for 2018 Yidan Prize, recognition in the field of medical education: development of curation methodologies for scientific content – 2018 Nominee, Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2018/10/21/nomination-for-2018-yidan-prize-recognition-in-the-field-of-medical-education-development-of-curation-methodologies-for-scientific-content-2018-nominee-aviva-lev-ari-phd-rn/

 

• 8/17/2018, Dr. Lev-Ari, PhD, RN was contacted by the President elect of the Massachusetts Academy of Sciences (MAS), Prof. Katya Ravid of Boston University, School of Medicine, to join MAS in the role of Liaison to the Biotechnology and eScientific Publishing industriesfor the term of August 2018-July 2021. In the MAS, Dr. Lev-Ari serve as Board member, Fellow, and Advisor to the Governing Board.

http://www.maacadsci.org

MAS FELLOWS 

GOVERNING BOARD

ACTIVITIES

 

• On 12/7/2018, Dr. Lev-Ari was nominated for 2019 Berkeley Alumna of the Year Achievement Award

2019 Awardees

https://awards.berkeley.edu/achievement-awards

 

4. Biography

PharmaceuticalIntelligence.com – 1,715,000 Views on 2/4/2020 since launch 4/2012

Aviva Lev-Ari, PhD, RN serves as

• Administrator of the platform and its architect since 4/2012, the venture inception. # Views by eReaders of Administrator’s posts +430,000
• Is the Launcher of the Website PharmaceuticalIntelligence.com
• Is the IP owner with agreements with each Expert, Author, Writer (EAW)
• Is the Editor-in-Chief of

1. the Journal [PharmaceuticalIntelligence.com] and of
2. the BioMed e-Series [https://pharmaceuticalintelligence.com/biomed-e-books/]

• Is the Co-Editor of several volumes in each series, except Series C: Cancer
• Is the Publisher of +3,300 of the 5,700 articles in the Journal
• Is the Developer of the Methodology of Curation for Pharmaceutics and Media top article 17,000 views, Several of Aviva’s articles fetch +10,000 views
• Is Developer of the Methodology of electronic Table of Contents (eTOCs) creation and was involved in the population of all eTOCs by Expert Editors that culled articles from the journal’s research categories to create ONE of a kind an eTOCs for each volume [except Series C: Cancer]
• Is Developer of the Methodology of Real Time Press Coverage of Top Biotech Conferences using social media and the ONE key stroke method for generation of the eProceedings.
• Is The Producer of 60 of the 70 Conference eProceedings in the venture’s Archive of Press Coverage of Biotech and Medical Conferences

https://pharmaceuticalintelligence.com/press-coverage/part-two-list-of-biotech-conferences-2013-to-present/

• Dr. Lev-Ari is the creator of THREE intellectual property asset classes in Media & Healthcare (pharmaceutical, medicine, medical devices & diagnostics, bioinformatics). The three archives are ready for Text Analysis & Text Mining by AI, ML and NLP algorithms
• The three archives consist of the following IP assets:

1. LPBI Journal:

https://lnkd.in/eEw5q7N

Open Access Online Scientific Journal PharmaceuticalIntelligence.com

• A collection of 5700 scientific articles +1.7 million eReaders, and
• The Journal Ontology of ~700 categories of Research

2. Sixteen volumes of Medical Books in Five specialties:

https://lnkd.in/ekWGNqA

Series A: Cardiovascular – 6 volumes, BUNDLED BY AMAZON.COM INTO A SIX-VOLUME SERIES FOR $515

https://lnkd.in/e6WkMgF

Series B: Genomics – 2 volumes

Series C: Cancer – 2 volumes

Series D: Immune system & Infectious Diseases – 3 volumes

Series E: Precision Medicine – 4 volumes

3. Biotech Conferences Press Coverage with Social Media:

• Lev-Ari is the Producer of Biotech & Medical Conference e-Proceedings:

https://lnkd.in/dc2qGAK

• Is the developer of the methodology for Real Time Press coverage with social media,
• The archive of 70 eProceeding documents was produced at 70 Biotech and Medical Conferences covered in Real Time during attendance
• Each Conferences yielded on average 4 – 5 new curations in the Journal

https://pharmaceuticalintelligence.com/press-coverage/part-three-conference-eproceedings-deliverables-social-media-analytics/

• Is the presenter of the Twitter Analytics of LPBI Group’s social media coverage of each conference by @pharma_BI and by @AVIVA1950

For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics  [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers]

• Is the creator of the 30 Collections of Tweets she posted in real time at 60 of the 70 BioTech and Medical Conferences listed in Part Two: List of BioTech Conferences 2013 to Present

https://pharmaceuticalintelligence.com/press-coverage/

• Part One: The Process of Real Time Coverage using Social Media
• Part Two: List of BioTech Conferences 2013 to Present
• Part Three: Conference eProceedings DELIVERABLES & Social Media Analytics

An Inspirational Case Study in Entrepreneurship

The immaculate CONCEPTION of LPBI Group

Launching a Journal to publish the combination drug therapy, I developed in 2006 !!

Milestones in a unique academic, technical training and work experience

• it was my MASTERS in planning at HUJI, GPA 95
• The conceptualization modeling I did at Technion, independently
• It was the PhD in Industrial Organization Economics at Berkeley, and the business portfolio analytics inside my dissertation chapters 6 to 9
• My concept development at SRI, MITRE, PSC (software Pricing Models, valuation of search algorithms) and modeling at McGraw-Hill
• My 15 courses in biological science at NEU.edu in 2005
• My RN, three years, 70 units, plus PharmacoTherapy research with my Prof. of Pharmacology, developing on my own a combination drug therapy, bring the professor to be stunned, he was not familiar with one of the three drug, never thought of that drug combination  for cardiovascular before, six papers, followed.
• My five years in Hearth care delivery at MGH, BIDMC, Waltham Hospital and post acute skilled nursing facilities as Clinical Nurse Manager.

 

UPDATED on 3/17/2018

• Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018

Prepared for publication in HUJI Alumni Magazine. Excerpts were Published in AFHU e-news on 5/11/2018.

https://us10.campaign-archive.com/?u=5c25136c60d4dfc4d3bb36eee&id=757c5c3aae&e=d09d2b8d72

https://www.afhu.org/2018/05/03/aviva-lev-ari/

 

• Recollections: Part 1 – My days at Berkeley, 9/1978 – 12/1983 – About my doctoral advisor, Allan Pred, other Professors and other Peers

 

• Recollections: Part 2 – “While Rolling” is preceded by “While Enrolling” Autobiographical Alumna Recollections of Berkeley – Aviva Lev-Ari, PhD’83

 

• On 3/31/2018 was nominated for 2018 Yidan Foundation Prize.

About the Yidan Prize

Founded in 2016 by Dr Charles CHEN Yidan, the Yidan Prize has a mission to create a better world through education. Through a series of initiatives – research, events and multimedia content – alongside the annual award, the prize serves to establish a platform that allows the global community to engage in conversation around education and to play a role in education philanthropy.

 On 9/27/2018 The Yidan Prize Announces Laureates 2018: 

The Yidan Prize’s laureates this year are Northwestern University’s Professor Larry HEDGES and eDX’s founder and CEO, Professor Anant AGARWAL.

From: Yidan Prize <info=yidanprize.org@mail241.atl171.mcdlv.net> on behalf of Yidan Prize <info@yidanprize.org>

Reply-To: Yidan Prize <info@yidanprize.org>

Date: Thursday, September 27, 2018 at 2:13 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: The Yidan Prize Announces Laureates 2018

 

LPBI Group’s BioMed e-series: e-Books in Medicine 

Aviva Lev-Ari, PhD, RN, Amazon’s Page

https://www.amazon.com/s/ref=nb_sb_noss?url=search-alias%3Ddigital-text&field-keywords=Aviva+Lev-Ari&rh=n%3A133140011%2Ck%3AAviva+Lev-Ari

 

• These are the multiple-volume FIVE e-Series in Medicine and Life Sciences:

Series A: e-Books on Cardiovascular Diseases

Series B: Frontiers in Genomics Research

Series C: e-Books on Cancer & Oncology

Series D: e-Books on BioMedicine – Metabolomics, Immunology, Infectious Diseases

Series E: Patient-Centered Medicine – LINKS to e-Books & Cover Pages for Volumes 1,2,3,4

 

• Table of Contents (eTOCs) of each Volume in the SIXTEEN-Volume BioMed e-Series

https://pharmaceuticalintelligence.com/2017/12/12/biomed-e-series-16-volumes-electronic-table-of-contents-of-each-volume/

 

 Aviva Lev-Ari’s articles in each volume

• 557 Co-Curations, Single Author Curations and Scientific Reports in 13 Volumes of LPBI’s BioMed e-Series by Aviva Lev-Ari, PhD, RN

https://www.linkedin.com/pulse/557-co-curations-single-author-curation-scientific-13-aviva/

• Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence: Contributions of Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2014/10/16/editorial-publication-of-articles-in-e-books-by-leaders-in-pharmaceutical-business-intelligence-contributions-of-aviva-lev-ari-phd-rn/

eScientific Media

 

Open Access Online Scientific Journal, Founder 

http://pharmaceuticalintelligence.com

BioMed e-Books Series – Editor-in-Chief

http://pharmaceuticalintelligence.com/biomed-e-books/

LinedIn Professional Profile

https://www.linkedin.com/today/author/avivalevari

LPBI Group FaceBook.com Page

http://www.facebook.com/LeadersInPharmaceuticalBusinessIntelligence

LPBI Group on Twitter.com 

http://twitter.com/pharma_BI

LPBI Group’s Company Page on LinkedIn

https://www.linkedin.com/company/9325543?trk=tyah&trkInfo=clickedVertical%3Acompany%2CclickedEntityId%3A9325543%2Cidx%3A1-1-1%2CtarId%3A1439226813927%2Ctas%3ALeaders%20in%20Pharmaceutica

LinkedIn (LI) Group Launcher and Manager of Three LI Groups

Cardiovascular Biotech & Pharma UK & US Networking Group

Leaders in Pharmaceutical Business Intelligence

Innovation in Israel

 

PULSE articles on LinkedIn N=+65

https://www.linkedin.com/in/avivalevari/detail/recent-activity/posts/

Key Opinion Leader (KOL) –

Aviva Lev-Ari, PhD, RN, as evidenced by

WE ARE ON AMAZON.COM – 1/1/2018 – 13 e-Books in Medicine and Life Sciences

https://www.amazon.com/s/ref=nb_sb_noss?url=search-alias%3Ddigital-text&field-keywords=Aviva+Lev-Ari&rh=n%3A133140011%2Ck%3AAviva+Lev-Ari

https://www.amazon.com/s/ref=dp_byline_sr_ebooks_9?ie=UTF8&text=Aviva+Lev-Ari&search-alias=digital-text&field-author=Aviva+Lev-Ari&sort=relevancerank

http://www.amazon.com/dp/B00DINFFYC

http://www.amazon.com/dp/B018Q5MCN8

http://www.amazon.com/dp/B018PNHJ84

http://www.amazon.com/dp/B018DHBUO6

http://www.amazon.com/dp/B013RVYR2K

http://www.amazon.com/dp/B012BB0ZF0

http://www.amazon.com/dp/B019UM909A

http://www.amazon.com/dp/B019VH97LU

http://www.amazon.com/dp/B071VQ6YYK

https://www.amazon.com/dp/B075CXHY1B

https://www.amazon.com/dp/B076HGB6MZ

https://www.amazon.com/dp/B078313281

https://www.amazon.com/dp/B078QVDV2W

 

FIVE years of e-Scientific Publishing @pharmaceuticalintellicence.com, Top Articles by Author and by e-Views >1,000, 4/27/2012 to 1/29/2018

Editor-in-Chief: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2017/04/28/five-years-of-e-scientific-publishing-pharmaceuticalintellicence-com-top-articles-by-author-and-by-e-views-1000-4272012-to-4272017/

 

Top Authors, by +5 years of e-Views, 1/29/2018, on pharmaceuticalintelligence.com

Editor-in-Chief: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2017/04/25/top-authors-by-5-years-of-e-views-4252017-on-pharmaceuticalintelligence-com/

 

Top Authors for all days ending 2018-01-29 (Summarized)

Author Curator Volume Editor BioMed E-Series Editor-in-Chief		All Time e-Views  2012-04-28 to 2018-01-29
Aviva Lev-Ari, PhD, RN [2012pharmaceutical]		352,153

 

Our TEAM		eViews: 5,934			Team Builder: Aviva Lev-Ari, PhD, RN
Founder			3,257			LPBI Group: Founder & Director, Aviva Lev-Ari, PhD, RN
BioMed e-Series			3,140			BioMed e-Series: Editor-in-Chief: Aviva Lev-Ari, PhD, RN Chief Scientific Officer: Larry H. Bernstein, MD, FCAP

Journal PharmaceuticalIntelligence.com	2,214		Editor-in-Chief:Aviva Lev-Ari, PhD, RN and  et al.
About	2,054		Author: Aviva Lev-Ari, PhD, RN
VISION  2,803 Author: Aviva Lev-Ari, PhD, RN LPBI Group  1,201 Founder: Aviva Lev-Ari, PhD, RN A selection of distinctive CURATIONS with high eViews volume Alternative Designs for the Human Artificial Heart: Patients in Heart Failure – Outcomes of Transplant (donor)/Implantation (artificial) and Monitoring Technologies for the Transplant/Implant Patient in the Community  2,776 Justin D. Pearlman, MD, PhD, FACC, Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN The Centrality of Ca(2+) Signaling and Cytoskeleton Involving Calmodulin Kinases and Ryanodine Receptors in Cardiac Failure, Arterial Smooth Muscle, Post-ischemic Arrhythmia, Similarities and Differences, and Pharmaceutical Targets  3,138 Larry H. Bernstein, MD, FCAP, Justin D. Pearlman, MD, PhD and Aviva Lev-Ari, PhD, RN    Sternotomy after prior CABG, MVR, AVR, or Radiation; Complications of PCI; Sepsis from Cardiovascular Interventions  1,598 Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN Dealing with the Use of the High Sensitivity Troponin (hs cTn) Assays  1,472 Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran)  11,606 Vivek Lal, MBBS, MD, FCIR, Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN Treatment of Refractory Hypertension via Percutaneous Renal Denervation  1,085 Curator: Aviva Lev-Ari, PhD, RN Interview with the co-discoverer of the structure of DNA: Watson on The Double Helix and his changing view of Rosalind Franklin 1,230 Curator: Aviva Lev-Ari, PhD, RN

Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care

5,865

Curator: Aviva Lev-Ari, PhD, RN

Bystolic’s generic Nebivolol – Positive Effect on circulating Endothelial Progenitor Cells Endogenous Augmentation

1,059

Author and Curator: Aviva Lev-Ari, PhD, RN

Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes

1,339

Curator: Aviva Lev-Ari, PhD, RN

Mitral Valve Repair: Who is a Patient Candidate for a Non-Ablative Fully Non-Invasive Procedure?

1,493

Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN

Clinical Trials Results for Endothelin System: Pathophysiological role in Chronic Heart Failure, Acute Coronary Syndromes and MI – Marker of Disease Severity or Genetic Determination?	1,472		Author and Curator: Aviva Lev-Ari, PhD, RN
Peroxisome proliferator-activated receptor (PPAR-gamma) Receptors Activation: PPARγ transrepression for Angiogenesis in Cardiovascular Disease and PPARγ transactivation for Treatment of Diabetes	1,919		Author and Curator: Aviva Lev-Ari, PhD, RN

1. New e-Book TITLES forthcoming on Amazon.com in 2018 from LPBI Group’s BioMed e-Series 

• Volume Five:Pharmacological Agents in Treatment of Cardiovascular Diseases

Work-in-Progress

https://pharmaceuticalintelligence.com/biomed-e-books/series-a-e-books-on-cardiovascular-diseases/volume-five-pharmaco-therapies-for-cvd/

• Volume Six: Interventional Cardiology and Cardiac Surgery for Disease Diagnosis and Guidance of Treatment

Work-in-Progress

https://pharmaceuticalintelligence.com/biomed-e-books/series-a-e-books-on-cardiovascular-diseases/volume-six-interventional-cardiology-and-cardiac-surgery/

• Genomics Volume 2: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome OntologyWork-in-Progresshttps://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/volume-two-genomics-methodologies-ngs-bioinformatics-simulations-and-the-genome-ontology/

On June 19, 2016 – We Celebrate reaching over One Million e-Readers @PharmaceuticalIntelligence.com

https://pharmaceuticalintelligence.com/2016/06/19/june-19-2016-we-celebrate-reaching-over-one-million-e-readers-pharmaceuticalintelligence-com/

REAL TIME Press Coverage for Biotech and Medicine, Scientific and Business Investment International Conferences

https://pharmaceuticalintelligence.com/press-coverage/

Founder – Links to CV and Publications

https://pharmaceuticalintelligence.com/founder/

Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence: Contributions of Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2014/10/16/editorial-publication-of-articles-in-e-books-by-leaders-in-pharmaceutical-business-intelligence-contributions-of-aviva-lev-ari-phd-rn/

Corporate Clients for our Services: Funding Medical Devices Development & Biologics

https://pharmaceuticalintelligence.com/joint-ventures/corporate-clients-for-our-services/

 

BIO

1985 – 2005, Aviva Lev-Ari worked at Director Level with Start-ups and Fortune 100 companies making presentations at the CEO Board Room level. Is reinventing work so that it works for the digital global economy. Consults and speaks to large and small groups. Lead webinars for universities, corporations and associations, and generally stir up conversation and inquiry on industry trends.
Startups: TimeØ Group, Concept Five Technologies, Inc., MDSS, Inc.; Top Tier Management Consulting: SRI International, Monitor Group; OEM: Amdahl Corporation; Top 6th System Integrator: Perot System Corporation; FFRDC: MITRE Corporation. In the Publishing industry: was Director of Research at McGraw-Hill/CTB. Researcher on Cardiovascular Pharmaco-therapy at Bouve College of Health Sciences, Northeastern University.

For a detailed CV for 1985 – 2005, go to

LinedIn Professional Profile

https://www.linkedin.com/today/author/avivalevari

CV in e-Scientific Publishing

In 4/2012, Aviva Lev-Ari, PhD, RN has launched LPBI Group. She is an Executive-Entrepreneur with high energy and passion. Followed by 6200 Biotech professionals on LinkedIn, Group Manager of three Groups on LinkedIn in

(1) Pharmaceutical Intelligence,

(2) Cardiovascular Disease and

(3) Innovations in Israel.

Dr. Lev-Ari’s business acumen is at the intersection of

(a) electronic Scientific Media,

(b) Drug Discovery and

(c) Venture Funding.

LPBI Group is an early stage start up in three domains:

(1) Knowledge-based Informational Services

• Open Access OnLine Scientific Journal The Site Statistics on 9/14/2016: (1,053,618 e-Readers, 2,142 Subscribers, 4,892 Scientific Articles, ~8000 Comments by Scientists)
• BioMed e-Series, Five Series in Medicine, 8 e-Books on Amazon.com, 4 e-Books in 2016 and 3 e-Books in 2017
• Real Time Press Coverage of BioTech Global Premier Conferences, Portfolio of ~30 events have been covered in the last 3 years. In 2016, Dr. Lev-Ari has launched an
• Audio-Podcast Series in Medicine, 5 tracks – Development Status: PENDING
• Representation of US Patent Holders for Commercialization, Licensing and Partnerships

 

(2) Dr. Lev-Ari guides a Team of Scientists in Drug Discovery & Drug Delivery Research

• Drug Discovery with 3D BioPrinting
• Drug Delivery System – One solution for many agents for many indications

 

(3) As a Key Opinion Leader (KOL) Dr. Lev-Ari and her Team are involved in Business Financial Transactions (No Securities Traded)

• Funding Early Stage Ventures and Businesses, IP Licensing and Business Partnerships for MEDICAL DEVICES, Pharmaceutical Informational PLATFORMS and INVENTIONS IN BIOLOGICS.

 

HIGHLY ACCOMPLISHED DIRECTOR LEVEL

STRATEGIC TECHNOLOGY EXECUTIVE

PHARMACEUTICAL AND HEALTHCARE PROFESSIONAL

Seasoned technology executive with proven expertise running collaborative  teams in R&D and Operations in the areas of  electronic commerce, B2B transaction architecture design, Internet information analytics, data mining/modeling and  algorithm-based decision support systems.

World-class expert in design of intelligent decision-support systems. Ability to synthesize and apply research findings from diverse technical fields.  Command of Bayesian Theory and Hierarchical Modeling, neural-networks and simulated annealing techniques for data modeling and system-design implementation of Estimation procedures.

Strong team builder, leader, and sound communicator who holds outstanding analytical skills, extensive problem solving experience, and a persistent drive to exceed objectives and drive complex projects to completion and profitability.  Strategic thinker and skilled presenter who has proven effective at all levels of an organization.

Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence: Contributions of Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2014/10/16/editorial-publication-of-articles-in-e-books-by-leaders-in-pharmaceutical-business-intelligence-contributions-of-aviva-lev-ari-phd-rn/

By 9/27/2017, have curated 3,022 articles, the list of titles is on 153 pages on  http://pharmaceuticalintelligence.com

Links to each article to be found at

http://pharmaceuticalintelligence.com/?s=Aviva+Lev-Ari%2C+PhD%2C+RN

• Frontiers in Cardiology and Cardiovascular Disorders – 435 articles 

https://pharmaceuticalintelligence.com/wp-admin/edit.php?s&post_status=all&post_type=post&author=34404001&action=-1&m=0&cat=174907193&filter_action=Filter&paged=1&action2=-1

• Cardiovascular Surgical Procedures  – 192  articles

https://pharmaceuticalintelligence.com/wp-admin/edit.php?s&post_status=all&post_type=post&author=34404001&action=-1&m=0&cat=174907594&filter_action=Filter&paged=1&action2=-1

 

• On 4/30/2012, First article in the Journal pharmaceuticalintelligence.com was published
• On 9/27/2017, all Journal articles were viewed by 1,298,700 e-Readers on 
• On 9/29/2017, Journal archive comprises of 5,191 scientific articles

 

Internet e-REACH Author, Curator and Editor-in-Chief	Views on 9/27/2017 since 4/30/2012	Journal Articles published on 9/27/2017 since 4/30/2012
Aviva Lev-Ari, PhD, RN All Authors	336,640 1,298,700	3,022 5,191

For Venture’s Vision go to

http://pharmaceuticalintelligence.com/vision/

http://pharmaceuticalintelligence.com/open-access-scientific-journal/about/

For Complete Biography and CV go to 

http://pharmaceuticalintelligence.com/founder/

For the Series of e-Books (electronic Books) in BioMedicine go to 

http://pharmaceuticalintelligence.com/biomed-e-books/

For Scoop.it! Journal on Cardiovascular and Vascular Imaging, go to 

http://www.scoop.it/t/cardiovascular-and-vascular-imaging/

For Scoop.it! Journal on Cardiovascular Pharmaco-therapy

http://www.scoop.it/t/cardiovascular-disease-pharmaco-therapy

Roles at Leaders of Pharmaceutical Business Intelligence

(LPBI) Group

Journal and BioMed e-Series Editor-in-Chief, 4/30/2012 to Present

I. Open Access Online Scientific Journal launched by Dr. Lev-Ari in 4/2012:

http://pharmaceuticalintelligence.com.

II. BioMed e-Series was launched by Dr. Lev-Ari in 10/2012:

III.   Editorials of Scientific Biotech Conference Event Coverage

http://pharmaceuticalintelligence.com/press-coverage/

via our Open Access Scientific Journal

http://pharmaceuticalintelligence.com

Scientific Journal Site Statistics

Date |Views to Date |# of articles |NIH Clicks |Nature Clicks

07/29/2013   217,356 1,138 1,389 705
12/01/2013   287,645 1,428 1,676 828
02/09/2014   325,039 1,665 1,793 892
03/05/2014   338,958 1,717 1,830 965
03/21/2014   347,667 1,750 1,838 974

03/31/2014  352,683 1,768 1,869 991

05/12/2014  373.696  1,878  1,944  1,035

06/18/2014  393,111  1,992  1,982  1,087

7/27/2014  418,570  2,098  2.050  1,124

9/2/2014  444,222  2,226  2,104  1,170

10/9/2014 471,117  2,337  2,147  1,216

11/4/2014  492,736  2,471  2,194 1,234

2/15/2015  572,027 2,727  2,358  1,345

3/10/2015 591,520 2,808 2,373 1,369

6/7/2015   661,215 3,007 2,562 1,535

7/27/2015 694,298 3,085 2,583 1,572

8/18/2015 709,609  3,173 2,613 1,573

02/18/2016  886,454  4,162   2,911  1,813 

Date |Views to Date |# of articles |NIH Clicks |Nature Clicks

12/1/2016 9/27/2017

1,107,643  1,298,700

4,972 5,191

3,398 3,878

2,279 2,922

 

We Celebrate 5,000 Scientific Articles @pharmaceuticalintelligence.com – 2016 was a GREAT Year !!!!!

https://pharmaceuticalintelligence.com/2016/12/19/we-celebrate-5000-scientific-articles-pharmaceuticalintelligence-com-2016-was-a-great-year/ 

 

BioMed e-Series of e-Books

Larry Bernstein, MD FACP and Aviral Vatsa, MBBS, PhD, Editors               

The BioMedicine e- Book Series is planning the publication of the following e-Books Titles with Amazon KINDLE

• Perspectives on Nitric Oxide in Disease Mechanisms (2013),

http://www.amazon.com/dp/B00DINFFYC

Target Market: CARDIOLOGISTS

• Cardiovascular Diseases: Causes, Risks and Management

Justin D. Pearlman MD ME PhD MA FACC, Editor

• Series A: Cardiovascular Diseases

Content Consultant: Justin D. Pearlman MD ME PhD MA FACC

• Volume One: Perspectives on Nitric Oxide in Disease Mechanisms
• Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation
• Volume Three: Etiologies of Cardiovascular Diseases – Epigenetics, Genetics & Genomics
• Volume Four: Therapeutic Promise: Cardiovascular Diseases, Regenerative & Translational Medicine
• Volume Five: Pharmaco-Therapies for Cardiovascular Diseases
• Volume Six: Interventional Cardiology, Cardiac Surgery and Cardiovascular Imaging for Disease Diagnosis and Guidance of Treatment

Target Market: CARDIOLOGISTS

• Genomics Orientations for Personalized Medicine 

Larry Bernstein, MD FACP, Sr. Editor, SJ Williams, PhD and Aviva Lev-Ari, PhD, RN, Editors  


Target Market: Life Scientists and BIG PARMA, Academia and the Public

• Metabolic Genomics & Pharmaceutics (2015)
  

Larry Bernstein, MD, FACP, Editor


Target Market: GI MDs, Nutritionists, Food Industry, Academia and the Public

Larry Bernstein, MD, FACP, Editor



• Milestones in Physiology: Discoveries in Medicine, Genomics and Therapeutics, 2015

Target Market: Medical Students and Physicians in the Community

• Cancer Biology and Genomics for Disease Diagnosis (2015),


SJ. Williams, PhD, Sr. Editor,  Tilda Barliya, PhD and Ritu Saxena, PhD, Editors


Target Market: ONCOLOGISTS

• Therapies in Cancer: Surgery, Radiation, Chemo and Immunotherapies 2016

Target Market: ONCOLOGISTS

• Nanotechnology in Drug Delivery (2016),

Dr. Tilda Barliya, Editor


Target Market: BIG PHARMA & Academics

• Human Immune System in Health and in Disease – 2016 – Editor TBA

• Infectious Disease & New Antibiotic Targets – 2016 – Editor TBA

Roles at http://pharmaceuticalintelligence.com

Expert, Author, Writer and Category OWNER of:

• Ecosystems & Industrial Concentration in the Medical Device Sector
• Pharmacotherapy of Cardiovascular Disease
• Genomic Testing: Methodology for Diagnosis with Dr. Larry Bernstein
• Pharmaceutical Industry Competitive Intelligence

  

PUBLICATIONS

Cardiovascular Diseases and Pharmacological Therapy

Lev-Ari, A. 2/4/2014. Is Pharmacogenetic-based Dosing of Warfarin Superior for Anticoagulation Control?

http://pharmaceuticalintelligence.com/2014/02/04/is-pharmacogenetic-based-dosing-of-warfarin-superior-for-anticoagulation-control/

Lev-Ari, A. 2/2/2014. Prolonged Wakefulness: Lack of Sufficient Duration of Sleep as a Risk Factor for Cardiovascular Diseases – Indications for Cardiovascular Chrono-therapeutics

http://pharmaceuticalintelligence.com/2014/02/02/prolonged-wakefulness-lack-of-sufficient-duration-of-sleep-as-a-risk-factor-for-cardiovascular-diseases-indications-for-cardiovascular-chrono-therapeutics/

Lev-Ari, A. 1/30/2014. Testosterone Therapy for Idiopathic Hypogonadotrophic Hypogonadism has Beneficial and Deleterious Effects on Cardiovascular Risk Factors

http://pharmaceuticalintelligence.com/2014/01/30/testosterone-therapy-for-idiopathic-hypogonadotrophic-hypogonadism-has-beneficial-and-deleterious-effects-on-cardiovascular-risk-factors/

Lev-Ari, A. 1/28/2014. Calcium and Cardiovascular Diseases: A Series of Twelve Articles in Advanced Cardiology

http://pharmaceuticalintelligence.com/2014/01/28/calcium-and-cardiovascular-diseases-a-series-of-twelve-articles-in-advanced-cardiology/

Lev-Ari, A. 1/22/2014. Acute Myocardial Infarction: Curations of Cardiovascular Original Research – A Bibliography

http://pharmaceuticalintelligence.com/2014/01/22/acute-myocardial-infarction-curations-of-cardiovascular-original-research-a-bibliography/

Lev-Ari, A. 1/21/2014. 2014 Winter in New England: The Effect of Record Cold Temperatures on Cardiovascular Diseases

http://pharmaceuticalintelligence.com/2014/01/21/2014-winter-in-new-england-the-effect-of-record-cold-temperatures-on-cardiovascular-diseases/ 

Lev-Ari, A. 1/15/2014, Regeneration: Cardiac System (cardiomyogenesis) and Vasculature (angiogenesis)

http://pharmaceuticalintelligence.com/2014/01/15/regeneration-cardiac-system-and-vasculature

Lev-Ari, A. 1/4/2014, conceived: NEW Definition for Co-Curation in Medical Research

http://pharmaceuticalintelligence.com/2014/01/04/conceived-new-definition-for-co-curation-in-medical-research/

Lev-Ari, A. 12/10/2013, The Young Surgeon and The Retired Pathologist: On Science, Medicine and HealthCare Policy – The Best Writers Among the WRITERS

http://pharmaceuticalintelligence.com/2013/12/10/the-young-surgeon-and-the-retired-pathologist-on-science-medicine-and-healthcare-policy-best-writers-among-the-writers/

Pearlman JD and A. Lev-Ari, 11/4/2013, Mitral Valve Repair: Who is a Patient Candidate for a Non-Ablative Fully Non-Invasive Procedure?

http://pharmaceuticalintelligence.com/2013/11/04/mitral-valve-repair-who-is-a-candidate-for-a-non-ablative-fully-non-invasive-procedure/ 

Pearlman, JD and A. Lev-Ari, 9/30/2013 State of Cardiology on Wall Stress, Ventricular Workload and Myocardial Contractile Reserve: Aspects of Translational Medicine (TM) 

http://pharmaceuticalintelligence.com/2013/09/30/state-of-cardiology-on-wall-stress-ventricular-workload-and-myocardial-contractile-reserve-aspects-of-translational-medicine/

Lev-Ari A., 9/25/2013 Diabetes-risk Forecasts: Serum Calcium in Upper-Normal Range (>2.5 mmol/L) as a New Biomarker 

http://pharmaceuticalintelligence.com/2013/09/25/diabetes-risk-forecasts-serum-calcium-in-upper-normal-range-2-5-mmoll-as-a-new-biomarker/

Lal V., Pearlman, JD and A. Lev-Ari, 9/23/2013 Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) or PRADAXA (dabigatran)

http://pharmaceuticalintelligence.com/2013/09/23/do-novel-anticoagulants-affect-the-ptinr-the-cases-of-xarelto-rivaroxaban-and-pradaxa-dabigatran/

Pearlman JD, Bernstein LH and A. Lev-Ari, 9/16/2013 Calcium-Channel Blocker, Calcium Release-related Contractile Dysfunction (Ryanopathy) and Calcium as Neurotransmitter Sensor

http://pharmaceuticalintelligence.com/2013/09/16/calcium-channel-blocker-calcium-as-neurotransmitter-sensor-and-calcium-release-related-contractile-dysfunction-ryanopathy/

Bernstein LH, Pearlman JD and A. Lev-Ari, 9/12/2013 Disruption of Calcium Homeostasis: Cardiomyocytes and Vascular Smooth Muscle Cells: The Cardiac and Cardiovascular Calcium Signaling Mechanism

http://pharmaceuticalintelligence.com/2013/09/12/disruption-of-calcium-homeostasis-cardiomyocytes-and-vascular-smooth-muscle-cells-the-cardiac-and-cardiovascular-calcium-signaling-mechanism/

Bernstein LH and A. Lev-Ari, 9/10/2013 Synaptotagmin functions as a Calcium Sensor: How Calcium Ions Regulate the fusion of vesicles with cell membranes during Neurotransmission

http://pharmaceuticalintelligence.com/2013/09/10/synaptotagmin-functions-as-a-calcium-sensor-how-calcium-ions-regulate-the-fusion-of-vesicles-with-cell-membranes-during-neurotransmission/

Pearlman, JD, Bernstein, HL and A. Lev-Ari 8/28/2013 Cardiac Contractility & Myocardium Performance: Ventricular Arrhythmias and Non-ischemic Heart Failure – Therapeutic Implications for Cardiomyocyte Ryanopathy (Calcium Release-related Contractile Dysfunction) and Catecholamine Responses

http://pharmaceuticalintelligence.com/2013/08/28/cardiac-contractility-myocardium-performance-ventricular-arrhythmias-and-non-ischemic-heart-failure-therapeutic-implications-for-cardiomyocyte-ryanopathy-calcium-release-related-contractile/

Pearlman JD and A. Lev-Ari 8/25/2013 Coronary Circulation Combined Assessment: Optical Coherence Tomography (OCT), Near-Infrared Spectroscopy (NIRS) and Intravascular Ultrasound (IVUS) – Detection of Lipid-Rich Plaque and Prevention of Acute Coronary Syndrome (ACS)

http://pharmaceuticalintelligence.com/2013/08/25/coronary-circulation-combined-assessment-optical-coherence-tomography-oct-near-infrared-spectroscopy-nirs-and-intravascular-ultrasound-ivus-detection-of-lipid-rich-plaque-and-prevention-of-a/

Lev-Ari, A 8/1/2013 Calcium Cycling (ATPase Pump) in Cardiac Gene Therapy: Inhalable Gene Therapy for Pulmonary Arterial Hypertension and Percutaneous Intra-coronary Artery Infusion for Heart Failure: Contributions by Roger J. Hajjar, MD

http://pharmaceuticalintelligence.com/2013/08/01/calcium-molecule-in-cardiac-gene-therapy-inhalable-gene-therapy-for-pulmonary-arterial-hypertension-and-percutaneous-intra-coronary-artery-infusion-for-heart-failure-contributions-by-roger-j-hajjar/

Bernstein, HL, Pearlman, JD and A. Lev-Ari 8/5/2013 Alternative Designs for the Human Artificial Heart: The Patients in Heart Failure – Outcomes of Transplant (donor)/Implantation (artificial) and Monitoring Technologies for the Transplant/Implant Patient in the Community

http://pharmaceuticalintelligence.com/2013/08/05/alternative-designs-for-the-human-artificial-heart-the-patients-in-heart-failure-outcomes-of-transplant-donorimplantation-artificial-and-monitoring-technologies-for-the-transplantimplant-pat/

Lev-Ari, A 7/29/2013 Cardiovascular Original Research: Cases in Methodology Design for Content Curation and Co-Curation

http://pharmaceuticalintelligence.com/2013/07/29/cardiovascular-original-research-cases-in-methodology-design-for-content-curation-and-co-curation/

Pearlman, JD and A. Lev-Ari 7/23/2013 Cardiovascular Complications: Death from Reoperative Sternotomy after prior CABG, MVR, AVR, or Radiation; Complications of PCI; Sepsis from Cardiovascular Interventions

http://pharmaceuticalintelligence.com/2013/07/23/cardiovascular-complications-of-multiple-etiologies-repeat-sternotomy-post-cabg-or-avr-post-pci-pad-endoscopy-andor-resultant-of-systemic-sepsis/

Pearlman, JD and A. Lev-Ari 7/22/2013 Cardiac Resynchronization Therapy (CRT) to Arrhythmias: Pacemaker/Implantable Cardioverter Defibrillator (ICD) Insertion 

http://pharmaceuticalintelligence.com/2013/07/22/cardiac-resynchronization-therapy-crt-to-arrhythmias-pacemakerimplantable-cardioverter-defibrillator-icd-insertion/

Lev-Ari, A. 7/19/2013 3D Cardiovascular Theater – Hybrid Cath Lab/OR Suite, Hybrid Surgery, Complications Post PCI and Repeat Sternotomy 

http://pharmaceuticalintelligence.com/2013/07/19/3d-cardiovascular-theater-hybrid-cath-labor-suite-hybrid-surgery-complications-post-pci-and-repeat-sternotomy/

Pearlman, JD and A. Lev-Ari 7/17/2013 Emerging Clinical Applications for Cardiac CT: Plaque Characterization, SPECT Functionality, Angiogram’s and Non-Invasive FFR 

http://pharmaceuticalintelligence.com/2013/07/17/emerging-clinical-applications-for-cardiac-ct-plaque-characterization-spect-functionality-angiograms-and-non-invasive-ffr/

Lev-Ari, A. 7/14/2013 Vascular Surgery: International, Multispecialty Position Statement on Carotid Stenting, 2013 and Contributions of a Vascular Surgeon at Peak Career – Richard Paul Cambria, MD

http://pharmaceuticalintelligence.com/2013/07/14/vascular-surgery-position-statement-in-2013-and-contributions-of-a-vascular-surgeon-at-peak-career-richard-paul-cambria-md-chief-division-of-vascular-and-endovascular-surgery-co-director-thoracic/

Lev-Ari, A. 7/9/2013 Heart Transplant (HT) Indication for Heart Failure (HF): Procedure Outcomes and Research on HF, HT @ Two Nation’s Leading HF & HT Centers 

http://pharmaceuticalintelligence.com/2013/07/09/research-programs-george-m-linda-h-kaufman-center-for-heart-failure-cleveland-clinic/

Lev-Ari, A. 7/8/2013 Becoming a Cardiothoracic Surgeon: An Emerging Profile in the Surgery Theater and through Scientific Publications  

http://pharmaceuticalintelligence.com/2013/07/08/becoming-a-cardiothoracic-surgeon-an-emerging-profile-in-the-surgery-theater-and-through-scientific-publications/

Pearlman, JD and A. Lev-Ari  7/4/2013 Fractional Flow Reserve (FFR) & Instantaneous wave-free ratio (iFR): An Evaluation of Catheterization Lab Tools (Software Validation) for Ischemic Assessment (Diagnostics) – Change in Paradigm: The RIGHT vessel not ALL vessels 

http://pharmaceuticalintelligence.com/2013/07/04/fractional-flow-reserve-ffr-instantaneous-wave-free-rario-ifr-an-evaluation-of-catheterization-lab-tools-for-ischemic-assessment/

Lev-Ari, A. 7/1/22013 Endovascular Lower-extremity Revascularization Effectiveness: Vascular Surgeons (VSs), Interventional Cardiologists (ICs) and Interventional Radiologists (IRs) 

http://pharmaceuticalintelligence.com/2013/07/01/endovascular-lower-extremity-revascularization-effectiveness-vascular-surgeons-vss-interventional-cardiologists-ics-and-interventional-radiologists-irs/

Lev-Ari, A. 6/10/2013 No Early Symptoms – An Aortic Aneurysm Before It Ruptures – Is There A Way To Know If I Have it?

http://pharmaceuticalintelligence.com/2013/06/10/no-early-symptoms-an-aortic-aneurysm-before-it-ruptures-is-there-a-way-to-know-if-i-have-it/

Lev-Ari, A. 6/9/2013 Congenital Heart Disease (CHD) at Birth and into Adulthood: The Role of Spontaneous Mutations

http://pharmaceuticalintelligence.com/2013/06/09/congenital-heart-disease-at-birth-and-into-adulthood-the-role-of-spontaneous-mutations-the-genes-and-the-pathways/

Lev-Ari, A. 6/3/2013 Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care 

http://pharmaceuticalintelligence.com/2013/06/03/clinical-indications-for-use-of-inhaled-nitric-oxide-ino-in-the-adult-patient-market-clinical-outcomes-after-use-therapy-demand-and-cost-of-care/

Lev-Ari, A. 6/2/2013 Inhaled Nitric Oxide in Adults: Clinical Trials and Meta Analysis Studies – Recent Findings 

http://pharmaceuticalintelligence.com/2013/06/02/inhaled-nitric-oxide-in-adults-with-acute-respiratory-distress-syndrome/

Pearlman, JD and A. Lev-Ari 5/24/2013 Imaging Biomarker for Arterial Stiffness: Pathways in Pharmacotherapy for Hypertension and Hypercholesterolemia Management

http://pharmaceuticalintelligence.com/2013/05/24/imaging-biomarker-for-arterial-stiffness-pathways-in-pharmacotherapy-for-hypertension-and-hypercholesterolemia-management/

Pearlman, JD and A. Lev-Ari 5/22/2013 Acute and Chronic Myocardial Infarction: Quantification of Myocardial Perfusion Viability – FDG-PET/MRI vs. MRI or PET alone

http://pharmaceuticalintelligence.com/2013/05/22/acute-and-chronic-myocardial-infarction-quantification-of-myocardial-viability-fdg-petmri-vs-mri-or-pet-alone/

Lev-Ari, A. 5/17/2013 Synthetic Biology: On Advanced Genome Interpretation for Gene Variants and Pathways: What is the Genetic Base of Atherosclerosis and Loss of Arterial Elasticity with Aging

http://pharmaceuticalintelligence.com/2013/05/17/synthetic-biology-on-advanced-genome-interpretation-for-gene-variants-and-pathways-what-is-the-genetic-base-of-atherosclerosis-and-loss-of-arterial-elasticity-with-aging/

Justin D Pearlman, HL Bernstein and A. Lev-Ari 5/15/2013 Diagnosis of Cardiovascular Disease, Treatment and Prevention: Current & Predicted Cost of Care and the Promise of Individualized Medicine Using Clinical Decision Support Systems

http://pharmaceuticalintelligence.com/2013/05/15/diagnosis-of-cardiovascular-disease-treatment-and-prevention-current-predicted-cost-of-care-and-the-promise-of-individualized-medicine-using-clinical-decision-support-systems-2/

Pearlman, JD and A. Lev-Ari 5/11/2013 Hypertension and Vascular Compliance: 2013 Thought Frontier – An Arterial Elasticity Focus

http://pharmaceuticalintelligence.com/2013/05/11/arterial-elasticity-in-quest-for-a-drug-stabilizer-isolated-systolic-hypertension-caused-by-arterial-stiffening-ineffectively-treated-by-vasodilatation-antihypertensives/

Pearlman, JD and A. Lev-Ari 5/7/2013 On Devices and On Algorithms: Arrhythmia after Cardiac Surgery Prediction and ECG Prediction of Paroxysmal Atrial Fibrillation Onset

http://pharmaceuticalintelligence.com/2013/05/07/on-devices-and-on-algorithms-arrhythmia-after-cardiac-surgery-prediction-and-ecg-prediction-of-paroxysmal-atrial-fibrillation-onset/

Pearlman, JD and A. Lev-Ari 5/4/2013 Cardiovascular Diseases: Decision Support Systems for Disease Management Decision Making

http://pharmaceuticalintelligence.com/2013/05/04/cardiovascular-diseases-decision-support-systems-for-disease-management-decision-making/

Lev-Ari, A. 5/3/2013 Gene, Meis1, Regulates the Heart’s Ability to Regenerate after Injuries.

http://pharmaceuticalintelligence.com/2013/05/03/gene-meis1-regulates-the-hearts-ability-to-regenerate-after-injuries/

Lev-Ari, A. 4/30/2013 Prostacyclin and Nitric Oxide: Adventures in Vascular Biology – A Tale of Two Mediators

http://pharmaceuticalintelligence.com/2013/04/30/prostacyclin-and-nitric-oxide-adventures-in-vascular-biology-a-tale-of-two-mediators/

Lev-Ari, A. 4/28/2013 Genetics of Conduction Disease: Atrioventricular (AV) Conduction Disease (block): Gene Mutations – Transcription, Excitability, and Energy Homeostasis

http://pharmaceuticalintelligence.com/2013/04/28/genetics-of-conduction-disease-atrioventricular-av-conduction-disease-block-gene-mutations-transcription-excitability-and-energy-homeostasis/

Lev-Ari, A. 4/25/2013 Economic Toll of Heart Failure in the US: Forecasting the Impact of Heart Failure in the United States – A Policy Statement From the American Heart Association

http://pharmaceuticalintelligence.com/2013/04/25/economic-toll-of-heart-failure-in-the-us-forecasting-the-impact-of-heart-failure-in-the-united-states-a-policy-statement-from-the-american-heart-association/

Lev-Ari, A. 4/24/2013 Harnessing New Players in Atherosclerosis to Treat Heart Disease

http://pharmaceuticalintelligence.com/2013/04/25/harnessing-new-players-in-atherosclerosis-to-treat-heart-disease/

Lev-Ari, A. 4/25/2013 Revascularization: PCI, Prior History of PCI vs CABG

http://pharmaceuticalintelligence.com/2013/04/25/revascularization-pci-prior-history-of-pci-vs-cabg/

Lev-Ari, A. 4/7/2013 Cholesteryl Ester Transfer Protein (CETP) Inhibitor: Potential of Anacetrapib to treat Atherosclerosis and CAD

http://pharmaceuticalintelligence.com/2013/04/07/cholesteryl-ester-transfer-protein-cetp-inhibitor-potential-of-anacetrapib-to-treat-atherosclerosis-and-cad/

Lev-Ari, A. 4/4/2013 Hypertriglyceridemia concurrent Hyperlipidemia: Vertical Density Gradient Ultracentrifugation a Better Test to Prevent Undertreatment of High-Risk Cardiac Patients

http://pharmaceuticalintelligence.com/2013/04/04/hypertriglyceridemia-concurrent-hyperlipidemia-vertical-density-gradient-ultracentrifugation-a-better-test-to-prevent-undertreatment-of-high-risk-cardiac-patients/

Lev-Ari, A. 4/3/2013 Fight against Atherosclerotic Cardiovascular Disease: A Biologics not a Small Molecule – Recombinant Human lecithin-cholesterol acyltransferase (rhLCAT) attracted AstraZeneca to acquire AlphaCore

http://pharmaceuticalintelligence.com/2013/04/03/fight-against-atherosclerotic-cardiovascular-disease-a-biologics-not-a-small-molecule-recombinant-human-lecithin-cholesterol-acyltransferase-rhlcat-attracted-astrazeneca-to-acquire-alphacore/

Lev-Ari, A. 3/31/2013 High-Density Lipoprotein (HDL): An Independent Predictor of Endothelial Function & Atherosclerosis, A Modulator, An Agonist, A Biomarker for Cardiovascular Risk

http://pharmaceuticalintelligence.com/2013/03/31/high-density-lipoprotein-hdl-an-independent-predictor-of-endothelial-function-artherosclerosis-a-modulator-an-agonist-a-biomarker-for-cardiovascular-risk/ 

Lev-Ari, A. 3/10/2013 Acute Chest Pain/ER Admission: Three Emerging Alternatives to Angiography and PCI

http://pharmaceuticalintelligence.com/2013/03/10/acute-chest-painer-admission-three-emerging-alternatives-to-angiography-and-pci/

Lev-Ari, A. and L H Bernstein 3/7/2013 Genomics & Genetics of Cardiovascular Disease Diagnoses: A Literature Survey of AHA’s Circulation Cardiovascular Genetics, 3/2010 – 3/2013

http://pharmaceuticalintelligence.com/2013/03/07/genomics-genetics-of-cardiovascular-disease-diagnoses-a-literature-survey-of-ahas-circulation-cardiovascular-genetics-32010-32013/

Lev-Ari, A. 2/28/2013 The Heart: Vasculature Protection – A Concept-based Pharmacological Therapy including THYMOSIN

http://pharmaceuticalintelligence.com/2013/02/28/the-heart-vasculature-protection-a-concept-based-pharmacological-therapy-including-thymosin/

Lev-Ari, A. 2/27/2013 Arteriogenesis and Cardiac Repair: Two Biomaterials – Injectable Thymosin beta4 and Myocardial Matrix Hydrogel

http://pharmaceuticalintelligence.com/2013/02/27/arteriogenesis-and-cardiac-repair-two-biomaterials-injectable-thymosin-beta4-and-myocardial-matrix-hydrogel/

Lev-Ari, A. 12/29/2012. Coronary artery disease in symptomatic patients referred for coronary angiography: Predicted by Serum Protein Profiles

http://pharmaceuticalintelligence.com/2012/12/29/coronary-artery-disease-in-symptomatic-patients-referred-for-coronary-angiography-predicted-by-serum-protein-profiles/

Bernstein, H Larry and Lev-Ari, A. 11/28/2012. Special Considerations in Blood Lipoproteins, Viscosity, Assessment and Treatment

http://pharmaceuticalintelligence.com/2012/11/28/special-considerations-in-blood-lipoproteins-viscosity-assessment-and-treatment/

Lev-Ari, A. 11/13/2012 Peroxisome proliferator-activated receptor (PPAR-gamma) Receptors Activation: PPARγ transrepression for Angiogenesis in Cardiovascular Disease and PPARγ transactivation for Treatment of Diabetes

http://pharmaceuticalintelligence.com/2012/11/13/peroxisome-proliferator-activated-receptor-ppar-gamma-receptors-activation-pparγ-transrepression-for-angiogenesis-in-cardiovascular-disease-and-pparγ-transactivation-for-treatment-of-dia/

Lev-Ari, A. 10/19/2012 Clinical Trials Results for Endothelin System: Pathophysiological role in Chronic Heart Failure, Acute Coronary Syndromes and MI – Marker of Disease Severity or Genetic Determination?

http://pharmaceuticalintelligence.com/2012/10/19/clinical-trials-results-for-endothelin-system-pathophysiological-role-in-chronic-heart-failure-acute-coronary-syndromes-and-mi-marker-of-disease-severity-or-genetic-determination/

Lev-Ari, A. 10/4/2012 Endothelin Receptors in Cardiovascular Diseases: The Role of eNOS Stimulation

http://pharmaceuticalintelligence.com/2012/10/04/endothelin-receptors-in-cardiovascular-diseases-the-role-of-enos-stimulation/

Lev-Ari, A. 10/4/2012 Inhibition of ET-1, ETA and ETA-ETB, Induction of NO production, stimulation of eNOS and Treatment Regime with PPAR-gamma agonists (TZD): cEPCs Endogenous Augmentation for Cardiovascular Risk Reduction – A Bibliography

http://pharmaceuticalintelligence.com/2012/10/04/inhibition-of-et-1-eta-and-eta-etb-induction-of-no-production-and-stimulation-of-enos-and-treatment-regime-with-ppar-gamma-agonists-tzd-cepcs-endogenous-augmentation-for-cardiovascular-risk-reduc/

Lev-Ari, A. 8/29/2012 Positioning a Therapeutic Concept for Endogenous Augmentation of cEPCs — Therapeutic Indications for Macrovascular Disease: Coronary, Cerebrovascular and Peripheral

http://pharmaceuticalintelligence.com/2012/08/29/positioning-a-therapeutic-concept-for-endogenous-augmentation-of-cepcs-therapeutic-indications-for-macrovascular-disease-coronary-cerebrovascular-and-peripheral/ 

Lev-Ari, A. 8/28/2012 Cardiovascular Outcomes: Function of circulating Endothelial Progenitor Cells (cEPCs): Exploring Pharmaco-therapy targeted at Endogenous Augmentation of cEPCs

http://pharmaceuticalintelligence.com/2012/08/28/cardiovascular-outcomes-function-of-circulating-endothelial-progenitor-cells-cepcs-exploring-pharmaco-therapy-targeted-at-endogenous-augmentation-of-cepcs/

Lev-Ari, A. 8/27/2012 Endothelial Dysfunction, Diminished Availability of cEPCs, Increasing CVD Risk for Macrovascular Disease – Therapeutic Potential of cEPCs

http://pharmaceuticalintelligence.com/2012/08/27/endothelial-dysfunction-diminished-availability-of-cepcs-increasing-cvd-risk-for-macrovascular-disease-therapeutic-potential-of-cepcs/

Lev-Ari, A. 8/24/2012 Vascular Medicine and Biology: CLASSIFICATION OF FAST ACTING THERAPY FOR PATIENTS AT HIGH RISK FOR MACROVASCULAR EVENTS Macrovascular Disease – Therapeutic Potential of cEPCs

http://pharmaceuticalintelligence.com/2012/08/24/vascular-medicine-and-biology-classification-of-fast-acting-therapy-for-patients-at-high-risk-for-macrovascular-events-macrovascular-disease-therapeutic-potential-of-cepcs/

Lev-Ari, A. 7/30/2012 Biosimilars: Intellectual Property Creation and Protection by Pioneer and by Biosimilar Manufacturers

http://pharmaceuticalintelligence.com/2012/07/30/biosimilars-intellectual-property-creation-and-protection-by-pioneer-and-by-biosimilar-manufacturers/

Lev-Ari, A. 7/29/2012 Biosimilars: Financials 2012 vs. 2008

http://pharmaceuticalintelligence.com/2012/07/30/biosimilars-financials-2012-vs-2008/

Lev-Ari, A. 7/29/2012 Biosimilars: CMC Issues and Regulatory Requirements

http://pharmaceuticalintelligence.com/2012/07/29/biosimilars-cmc-issues-and-regulatory-requirements/

Lev-Ari, A. 7/19/2012 Cardiovascular Disease (CVD) and the Role of agent alternatives in endothelial Nitric Oxide Synthase (eNOS) Activation and Nitric Oxide Production

http://pharmaceuticalintelligence.com/2012/07/19/cardiovascular-disease-cvd-and-the-role-of-agent-alternatives-in-endothelial-nitric-oxide-synthase-enos-activation-and-nitric-oxide-production/

Lev-Ari, A. 4/30/2012 Resident-cell-based Therapy in Human Ischaemic Heart Disease: Evolution in the PROMISE of Thymosin beta4 for Cardiac Repair

http://pharmaceuticalintelligence.com/2012/04/30/93/

Lev-Ari, A. 5/29/2012 Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes

http://pharmaceuticalintelligence.com/2012/05/29/445/

Lev-Ari, A. 7/2/2012 Macrovascular Disease – Therapeutic Potential of cEPCs: Reduction Methods for CV Risk

http://pharmaceuticalintelligence.com/2012/07/02/macrovascular-disease-therapeutic-potential-of-cepcs-reduction-methods-for-cv-risk/

Lev-Ari, A. 7/9/2012 Mitochondria Dysfunction and Cardiovascular Disease – Mitochondria: More than just the “powerhouse of the cell”

http://pharmaceuticalintelligence.com/2012/07/09/mitochondria-more-than-just-the-powerhouse-of-the-cell/

Lev-Ari, A. 7/16/2012 Bystolic’s generic Nebivolol – positive effect on circulating Endothelial Proginetor Cells endogenous augmentation

http://pharmaceuticalintelligence.com/2012/07/16/bystolics-generic-nebivolol-positive-effect-on-circulating-endothilial-progrnetor-cells-endogenous-augmentation/

Lev-Ari, A. & Abourjaily, P. (2006a) “An Investigation of the Potential of circulating Endothelial Progenitor Cells (cEPC) as a Therapeutic Target for Pharmacologic Therapy Design for Cardiovascular Risk Reduction.”Part I: Macrovascular Disease – Therapeutic Potential of cEPCs – Reduction methods for CV risk. Part II: (2006b) Therapeutic Strategy for cEPCs Endogenous Augmentation: A Concept-based Treatment Protocol for a Combined Three Drug Regimen. Part III: (2006c) Biomarker for Therapeutic Targets of Cardiovascular Risk Reduction by cEPCs Endogenous Augmentation using New Combination Drug Therapy of Three Drug Classes and Several Drug Indications. Northeastern University, Boston, MA 02115

Lev-Ari, A. Heart Vasculature (2007) Regeneration and Protection of Coronary Artery Endothelium and Smooth Muscle: A Concept-based Pharmacological Therapy of a Combined Three Drug Regimen. Bouve College of Health Sciences, Northeastern University, Boston, MA 02115

Cardiovascular Medical Devices: Cardiac Surgery, Cardiothoracic Surgical Procedures and Percutaneous Coronary Intervention (PCI) / Coronary Angioplasty

Lev-Ari, A. 1/26/2014. Transcatheter Valve Competition in the United States: Medtronic CoreValve infringes on Edwards Lifesciences Corp. Transcatheter Device Patents

http://pharmaceuticalintelligence.com/2014/01/26/transcatheter-valve-competition-in-the-united-states-medtronic-corevalve-infringes-on-edwards-lifesciences-corp-transcatheter-device-patents/

Lev-Ari, A. 1/26/2014. Developments on the Frontier of Transcatheter Aortic Valve Replacement (TAVR) Devices

http://pharmaceuticalintelligence.com/2014/01/26/developments-on-the-frontier-of-transcatheter-aortic-valve-replacement-tavr-devices/

Larry H. Bernstein and
Aviva Lev-Ari  6/23/2013 Survivals Comparison of Coronary Artery Bypass Graft (CABG) and Percutaneous Coronary Intervention (PCI) / Coronary Angioplasty

http://pharmaceuticalintelligence.com/2013/06/23/comparison-of-cardiothoracic-bypass-and-percutaneous-interventional-catheterization-survivals/

Larry H Bernstein and Lev-Ari, A. 6/23/2013 First case in the US: Valve-in-Valve (Aortic and Mitral) Replacements with Transapical Transcatheter Implants – The Use of Transfemoral Devices.

http://pharmaceuticalintelligence.com/2013/06/23/valve-in-valve-replacements-with-transapical-transcatheter-implants/

Larry H Bernstein and  Lev-Ari, A. 6/17/2013 Transcatheter Aortic Valve Replacement (TAVR): Postdilatation to Reduce Paravalvular Regurgitation During TAVR with a Balloon-expandable Valve

http://pharmaceuticalintelligence.com/2013/06/17/postdilatation-to-reduce-paravalvular-regurgitation-during-transcatheter-aortic-valve-replacement/



Larry H Bernstein and  Lev-Ari, A. 6/17/2013 Trans-apical Transcatheter Aortic Valve Replacement in a Patient with Severe and Complex Left Main Coronary Artery Disease (LMCAD)

http://pharmaceuticalintelligence.com/2013/06/17/management-of-difficult-trans-apical-transcatheter-aortic-valve-replacement-in-a-patient-with-severe-and-complex-arterial-disease/



Larry H Bernstein and  Lev-Ari, A. 6/18/2013 Ventricular Assist Device (VAD): A Recommended Approach to the Treatment of Intractable Cardiogenic Shock

http://pharmaceuticalintelligence.com/2013/06/18/a-recommended-approach-to-the-treatmnt-of-intractable-cardiogenic-shock/

Larry H Bernstein and  Lev-Ari, A.6/20/2013 Phrenic Nerve Stimulation in Patients with Cheyne-Stokes Respiration and Congestive Heart Failure

http://pharmaceuticalintelligence.com/2013/06/20/phrenic-nerve-stimulation-in-patients-with-cheyne-stokes-respiration-and-congestive-heart-failure/

Lev-Ari, A. 2/12/2013 Clinical Trials on transcatheter aortic valve replacement (TAVR) to be conducted by American College of Cardiology and the Society of Thoracic Surgeons

http://pharmaceuticalintelligence.com/2013/02/12/american-college-of-cardiologys-and-the-society-of-thoracic-surgeons-entrance-into-clinical-trials-is-noteworthy-read-more-two-medical-societies-jump-into-clinical-trial-effort-for-tavr-tech-f/

Lev-Ari, A. 12/31/2012 Renal Sympathetic Denervation: Updates on the State of Medicine

http://pharmaceuticalintelligence.com/2012/12/31/renal-sympathetic-denervation-updates-on-the-state-of-medicine/

Lev-Ari, A. 9/2/2012 Imbalance of Autonomic Tone: The Promise of Intravascular Stimulation of Autonomics

http://pharmaceuticalintelligence.com/2012/09/02/imbalance-of-autonomic-tone-the-promise-of-intravascular-stimulation-of-autonomics/

Lev-Ari, A. 8/13/2012 Coronary Artery Disease – Medical Devices Solutions: From First-In-Man Stent Implantation, via Medical Ethical Dilemmas to Drug Eluting Stents http://pharmaceuticalintelligence.com/2012/08/13/coronary-artery-disease-medical-devices-solutions-from-first-in-man-stent-implantation-via-medical-ethical-dilemmas-to-drug-eluting-stents/

Lev-Ari, A. 7/18/2012 Percutaneous Endocardial Ablation of Scar-Related Ventricular Tachycardia

http://pharmaceuticalintelligence.com/2012/07/18/percutaneous-endocardial-ablation-of-scar-related-ventricular-tachycardia/

Lev-Ari, A. 6/13/2012 Treatment of Refractory Hypertension via Percutaneous Renal Denervation

http://pharmaceuticalintelligence.com/2012/06/13/treatment-of-refractory-hypertension-via-percutaneous-renal-denervation/

Lev-Ari, A. 6/22/2012 Competition in the Ecosystem of Medical Devices in Cardiac and Vascular Repair: Heart Valves, Stents, Catheterization Tools and Kits for Open Heart and Minimally Invasive Surgery (MIS)

http://pharmaceuticalintelligence.com/2012/06/22/competition-in-the-ecosystem-of-medical-devices-in-cardiac-and-vascular-repair-heart-valves-stents-catheterization-tools-and-kits-for-open-heart-and-minimally-invasive-surgery-mis/

Lev-Ari, A. 6/19/2012 Executive Compensation and Comparator Group Definition in the Cardiac and Vascular Medical Devices Sector: A Bright Future for Edwards Lifesciences Corporation in the Transcatheter Heart Valve Replacement Market

http://pharmaceuticalintelligence.com/2012/06/19/executive-compensation-and-comparator-group-definition-in-the-cardiac-and-vascular-medical-devices-sector-a-bright-future-for-edwards-lifesciences-corporation-in-the-transcatheter-heart-valve-replace/

Lev-Ari, A. 6/22/2012 Global Supplier Strategy for Market Penetration & Partnership Options (Niche Suppliers vs. National Leaders) in the Massachusetts Cardiology & Vascular Surgery Tools and Devices Market for Cardiac Operating Rooms and Angioplasty Suites

http://pharmaceuticalintelligence.com/2012/06/22/global-supplier-strategy-for-market-penetration-partnership-options-niche-suppliers-vs-national-leaders-in-the-massachusetts-cardiology-vascular-surgery-tools-and-devices-market-for-car/

Lev-Ari, A. 7/23/2012 Heart Remodeling by Design: Implantable Synchronized Cardiac Assist Device: Abiomed’s Symphony

http://pharmaceuticalintelligence.com/2012/07/23/heart-remodeling-by-design-implantable-synchronized-cardiac-assist-device-abiomeds-symphony/

Lev-Ari, A. (2006b). First-In-Man Stent Implantation Clinical Trials & Medical Ethical Dilemmas. Bouve College of Health Sciences, Northeastern University, Boston, MA 02115

 

Curator: Medical Research

Lev-Ari, A. 2/27/2013 Ustekinumab New Drug Therapy for Cognitive Decline resulting from Neuroinflammatory Cytokine Signaling and Alzheimer’s Disease

http://pharmaceuticalintelligence.com/2013/02/27/ustekinumab-new-drug-therapy-for-cognitive-decline-resulting-from-neuroinflammatory-cytokine-signaling-and-alzheimers-disease/

Lev-Ari, A. 2/19/2013 Calcium (Ca) supplementation (>1400 mg/day): Higher Death Rates from all Causes and Cardiovascular Disease in Women

http://pharmaceuticalintelligence.com/2013/02/19/calcium-ca-supplementation-1400-mgday-higher-death-rates-from-all-causes-and-cardiovascular-disease-in-women/

Lev-Ari, A. 2/14/2013 Prostate Cancer: Androgen-driven “Pathomechanism” in Early-onset Forms of the Disease

http://pharmaceuticalintelligence.com/2013/02/14/prostate-cancer-androgen-driven-pathomechanism-in-early-onset-forms-of-the-disease/

Lev-Ari, A. 7/9/2012 Sunitinib brings Adult acute lymphoblastic leukemia (ALL) to Remission – RNA Sequencing – FLT3 Receptor Blockade

http://pharmaceuticalintelligence.com/2012/07/09/sunitinib-brings-adult-all-to-remission-rna-sequencing/

Mitochondria Dysfunction and Cardiovascular Disease – http://pharmaceuticalintelligence.com/2012/11/14/mitochondrial-dynamics-and-cardiovascular-diseases/ Part Two by Lev-Ari, A. (work-in-progress)

Curator: Genomics Research

Lev-Ari, A. 2/27/2013 Genomics & Ethics: DNA Fragments are Products of Nature or Patentable Genes?

http://pharmaceuticalintelligence.com/2013/02/27/genomics-ethics-dna-fragments-are-products-of-nature-or-patentable-genes/

Lev-Ari, A. 2/25/2013 Personalized Cardiovascular Genetic Medicine at Partners HealthCare and Harvard Medical School

http://pharmaceuticalintelligence.com/2013/02/25/center-for-personalized-genetic-medicine-partners-healthcare-and-harvard-medical-school/

Lev-Ari, A. 2/19/2013 NGS Market: Trends and Development for Genotype-Phenotype Associations Research

http://pharmaceuticalintelligence.com/2013/02/19/ngs-market-trends-and-development-for-genotype-phenotype-associations/

Lev-Ari, A. 2/11/2013, 2013 Genomics: The Era Beyond the Sequencing of the Human Genome: Francis Collins, Craig Venter, Eric Lander, et al.

http://pharmaceuticalintelligence.com/2013/02/11/2013-genomics-the-era-beyond-the-sequencing-human-genome-francis-collins-craig-venter-eric-lander-et-al/

Lev-Ari, A. 2/5/2013, Winning Over Cancer Progression: New Oncology Drugs to Suppress Passengers Mutations vs. Driver Mutations

http://pharmaceuticalintelligence.com/2013/02/05/winning-over-cancer-progression-new-oncology-drugs-to-suppress-driver-mutations-vs-passengers-mutations/

Lev-Ari, A. 1/13/2013, Paradigm Shift in Human Genomics – Predictive Biomarkers and Personalized Medicine – Part 1

http://pharmaceuticalintelligence.com/2013/01/13/paradigm-shift-in-human-genomics-predictive-biomarkers-and-personalized-medicine-part-1/

Curator & Reporter: FDA related Research and Regulations

Minimally Invasive Structural CVD Repairs: FDA grants 510(k) Clearance to Philips’ EchoNavigator – X-ray and 3-D Ultrasound Image Fused.

Curator: Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2013/03/21/minimally-invasive-structural-cvd-repairs-fda-grants-510k-to-philips-echonavigator-x-ray-and-3-d-ultrasound-image-fused/

FDA Pending 510(k) for The Latest Cardiovascular Imaging Technology

Curator: Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2013/01/28/fda-pending-510k-for-the-latest-cardiovascular-imaging-technology/

Demonstrate Biosimilarity: New FDA Biosimilar Guidelines

Reporter: Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2012/12/13/demonstrate-biosimilarity-new-fda-biosimilar-guidelines/

The FDA/CMS Summit For Biopharma Executives 2013: Prepare For Health Reform, December 10 & 11, 2012, WashDC

Reporter: Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2012/11/28/the-fdacms-summit-for-biopharma-executives-2013-prepare-for-health-reform-december-10-11-2012-washdc/

Xarelto (Rivaroxaban): Anticoagulant Therapy gains FDA New Indications and Risk Reduction for: (DVT) and (PE), while in use for Atrial fibrillation increase in Gastrointestinal (GI) Bleeding Reported

Reporter: Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2012/11/04/xarelto-rivaroxaban-anticoagulant-therapy-gains-fda-new-indications-and-risk-reduction-for-dvt-and-pe-while-in-use-for-atrial-fibrillation-increase-in-gastrointestinal-gi-bleeding-reported/

FDA Approval for Under-Skin Defibrillator goes to Boston Scientific Corporation

Reporter: Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2012/10/01/fda-approval-for-under-skin-defibrillator-goes-to-boston-scientific-corporation/

FDA: Strengthening Our National System for Medical Device Post-market Surveillance

Reporter: Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2012/09/07/fda-strengthening-our-national-system-for-medical-device-post-market-surveillance/

Not Having 510(k) Clearance, FDA advised Recall of Stryker’s Neptune following recall of pair of metal hip implants

Reporter; Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2012/08/02/stryker-recalls-pair-of-metal-hip-implants-halts-global-production/

23andMe Takes First Step Toward FDA Clearance

Reporter: Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2012/08/01/23andme-takes-first-step-toward-fda-clearance/

Gaps, Tensions, and Conflicts in the FDA Approval Process: Implications for Clinical Practice

Reporter: Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2012/07/31/gaps-tensions-and-conflicts-in-the-fda-approval-process-implications-for-clinical-practice/

Biosimilars: Intellectual Property Creation and Protection by Pioneer and by Biosimilar Manufacturers

Curator: Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2012/07/30/biosimilars-intellectual-property-creation-and-protection-by-pioneer-and-by-biosimilar-manufacturers/

Biosimilars: Financials 2012 vs. 2008

Curator: Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2012/07/30/biosimilars-financials-2012-vs-2008/

Biosimilars: CMC Issues and Regulatory Requirements

Curator: Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2012/07/29/biosimilars-cmc-issues-and-regulatory-requirements/